These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1046 related articles for article (PubMed ID: 22024527)

  • 1. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    Teeranaipong P; Sirivichayakul S; Mekprasan S; Ohata PJ; Avihingsanon A; Ruxrungtham K; Putcharoen O
    PLoS One; 2016; 11(4):e0154221. PubMed ID: 27120449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
    Marcelin AG; Descamps D; Tamalet C; Cottalorda J; Izopet J; Delaugerre C; Morand-Joubert L; Trabaud MA; Bettinger D; Rogez S; Ruffault A; Henquell C; Signori-Schmuck A; Bouvier-Alias M; Vallet S; Masquelier B; Flandre P; Calvez V;
    Antivir Ther; 2012; 17(1):119-23. PubMed ID: 22267476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    Diphoko T; Gaseitsiwe S; Kasvosve I; Moyo S; Okatch H; Musonda R; Wainberg M; Makhema J; Marlink R; Novitsky V; Essex M
    AIDS Res Hum Retroviruses; 2018 Aug; 34(8):667-671. PubMed ID: 29732907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
    Lapadula G; Calabresi A; Castelnuovo F; Costarelli S; Quiros-Roldan E; Paraninfo G; Ceresoli F; Gargiulo F; Manca N; Carosi G; Torti C
    Antivir Ther; 2008; 13(4):601-5. PubMed ID: 18672539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
    Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD;
    AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 drug resistance and associated factors among adults failing first-line highly active antiretroviral therapy in Ho Chi Minh City, Vietnam.
    Pham QD; Huynh TK; Luong TT; Tran T; Vu TX; Truong LX
    HIV Clin Trials; 2013; 14(1):34-44. PubMed ID: 23372113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
    Picchio GR; Rimsky LT; Van Eygen V; Haddad M; Napolitano LA; Vingerhoets J
    Antivir Ther; 2014; 19(8):819-23. PubMed ID: 24704709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
    Rimsky L; Van Eygen V; Hoogstoel A; Stevens M; Boven K; Picchio G; Vingerhoets J
    Antivir Ther; 2013; 18(8):967-77. PubMed ID: 23714781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
    Kiertiburanakul S; Wiboonchutikul S; Sukasem C; Chantratita W; Sungkanuparph S
    J Clin Virol; 2010 Apr; 47(4):330-4. PubMed ID: 20188624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.
    Saravanan S; Kausalya B; Gomathi S; Sivamalar S; Pachamuthu B; Selvamuthu P; Pradeep A; Sunil S; Mothi SN; Smith DM; Kantor R
    AIDS Res Hum Retroviruses; 2017 Jun; 33(6):567-574. PubMed ID: 27869478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
    Llibre JM; Santos JR; Puig T; Moltó J; Ruiz L; Paredes R; Clotet B
    J Antimicrob Chemother; 2008 Nov; 62(5):909-13. PubMed ID: 18653487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
    Pereira-Vaz J; Duque V; Pereira B; Mota V; Morais C; Saraiva-da-Cunha J; Meliço-Silvestre A
    J Med Virol; 2012 Apr; 84(4):551-4. PubMed ID: 22337292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.